loading page

BRIEF REPORT Outcomes following intolerance to calcineurin-inhibitor based graft-versus-host disease prophylaxis in children after allogeneic hematopoietic cell transplantation
  • +12
  • Ashok Srinivasan,
  • Diana Wu,
  • Ying Li,
  • YU BI,
  • Trevor Lannom M,
  • Deborah Ward,
  • Amr Qudeimat,
  • Renee Madden,
  • Akshay Sharma,
  • Rebecca Epperly,
  • Ewelina Mamcarz,
  • Aimee Talleur,
  • Swati Naik,
  • Subodh Selukar,
  • Brandon Triplett
Ashok Srinivasan
St Jude Children's Research Hospital Department of Oncology

Corresponding Author:[email protected]

Author Profile
Diana Wu
St Jude Children's Research Hospital Department of Oncology
Author Profile
Ying Li
St Jude Children's Research Hospital Department of Oncology
Author Profile
YU BI
St Jude Children's Research Hospital Department of Oncology
Author Profile
Trevor Lannom M
St Jude Children's Research Hospital Department of Oncology
Author Profile
Deborah Ward
St Jude Children's Research Hospital Department of Oncology
Author Profile
Amr Qudeimat
St Jude Children's Research Hospital Department of Oncology
Author Profile
Renee Madden
St Jude Children's Research Hospital Department of Oncology
Author Profile
Akshay Sharma
St Jude Children's Research Hospital Department of Oncology
Author Profile
Rebecca Epperly
St Jude Children's Research Hospital Department of Oncology
Author Profile
Ewelina Mamcarz
St Jude Children's Research Hospital Department of Oncology
Author Profile
Aimee Talleur
St Jude Children's Research Hospital Department of Oncology
Author Profile
Swati Naik
St Jude Children's Research Hospital Department of Oncology
Author Profile
Subodh Selukar
St Jude Children's Research Hospital Department of Oncology
Author Profile
Brandon Triplett
St Jude Children's Research Hospital Department of Oncology
Author Profile

Abstract

Calcineurin inhibitors (CNI), cyclosporine and tacrolimus, are commonly used for pharmacotherapeutic prophylaxis of Graft-vs.-Host disease after hematopoietic cell transplantation (HCT). Unfortunately, their use is associated with significant toxicities. While intolerance to CNI is well defined, there is very little data on how they impact outcomes after HCT in children. Our retrospective study in a cohort of 82 children, shows a high intolerance rate of 39% in this population associated with lower event free survival and a higher transplant-related mortality.
11 Apr 2023Submitted to Pediatric Blood & Cancer
11 Apr 2023Submission Checks Completed
11 Apr 2023Assigned to Editor
12 Apr 2023Review(s) Completed, Editorial Evaluation Pending
14 Apr 2023Reviewer(s) Assigned
02 May 2023Editorial Decision: Revise Major
22 May 2023Submission Checks Completed
22 May 2023Assigned to Editor
22 May 20231st Revision Received
22 May 2023Review(s) Completed, Editorial Evaluation Pending
22 May 2023Reviewer(s) Assigned
08 Jun 2023Editorial Decision: Accept